Henlius Partners With Amberstone on Next-Gen TCEs
Shanghai, China, September 24, 2026 Henlius has announced a strategic partnership with Amberstone Biosciences to discover and develop next-generation...
solid tumors
Advertisement
Leads Biolabs Gains Japan Orphan Drug Designation for Opamtistomig
NANJING, China — September 28, 2026 Leads Biolabs announced that opamtistomig (LBL-024), its investigational PD-L1/4-1BB bispecific antibody, has received...
Arvinas Doses First Patient in ARV-6723 Phase 1/2 Trial
NEW HAVEN, Conn. — September 28, 2026 Arvinas, Inc. announced that the first participant has been dosed in the...
HUTCHMED Initiates Global Phase I Trial of HMPL-A830
HONG KONG, SHANGHAI and FLORHAM PARK, N.J. — September 28, 2026 HUTCHMED (China) Limited announced the initiation of the...
Adagene Gains NMPA Clearance for ADG138 IND
SAN DIEGO and SUZHOU, China — September 22, 2026 Adagene announced that China’s National Medical Products Administration (NMPA) has...
Advertisements
AIM Highlights Ampligen Potential in Pancreatic Cancer
OCALA, Fla. — September 22, 2026 AIM ImmunoTech Inc. highlighted the potential role of Ampligen® (rintatolimod) in pancreatic cancer...
SystImmune Advances SI-B037 Into Phase 1/1b Trial
Redmond, Washington, U.S., September 22, 2026 SystImmune, Inc. has announced that the U.S. Food and Drug Administration (FDA) has...
Avacta Achieves Clinical Proof of Mechanism for AVA6103
LONDON and PHILADELPHIA — September 16, 2026 Avacta Therapeutics announced clinical proof of mechanism for AVA6103, its next-generation controlled-release...
Fennec Pharmaceuticals Presents Two-Year Pedmark Data in Japan
RESEARCH TRIANGLE PARK, N.C. — September 17, 2026 Fennec Pharmaceuticals announced the oral presentation of detailed results from the...
A2 Biotherapeutics Advances A2B395 in Solid Tumors
AGOURA HILLS, Calif. — September 15, 2026 A2 Biotherapeutics announced encouraging early safety and efficacy findings from the ongoing...
Advertisement
